Cocrystal Pharma, Inc. (COCP) — Institutional Holders, Q2 2026
28 institutional investment managers reported a COCP position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $1.2M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
COCP in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- TWO SIGMA INVESTMENTSNew · +175,379 sh+$184.1K
- VANGUARD CAPITAL MANAGEMENTAdded · +118,257 sh+$124.2K
- RENAISSANCE TECHNOLOGIESAdded · +55,700 sh+$58.5K
- CITADEL ADVISORSNew · +45,118 sh+$47.4K
- HRT FINANCIALNew · +20,336 sh+$21.4K
Biggest sellers
- T3 CompaniesSold out · -51,500 sh-$54.1K
- TWO SIGMA SECURITIESSold out · -15,255 sh-$16.0K
- GEODE CAPITAL MANAGEMENTTrimmed · -14,023 sh-$14.7K
- Virtu FinancialSold out · -13,080 sh-$13.7K
- XTX Topco LtdTrimmed · -6,689 sh-$7.0K
COCP 13F holders ranked 1–28 of 28
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT#1 · 358,228 sh | 358,228 | $376.1K | 0.00% | +49.3% |
| 2 | RENAISSANCE TECHNOLOGIES#2 · 179,628 sh | 179,628 | $188.6K | <0.01% | +44.9% |
| 3 | TWO SIGMA INVESTMENTS#3 · 175,379 sh | 175,379 | $184.1K | <0.01% | New |
| 4 | GEODE CAPITAL MANAGEMENT#4 · 76,208 sh | 76,208 | $80.0K | 0.00% | -15.5% |
| 5 | BlackRock#5 · 73,746 sh | 73,746 | $77.4K | 0.00% | 0.0% |
| 6 | CITADEL ADVISORS#6 · 45,118 sh | 45,118 | $47.4K | 0.00% | New |
| 7 | Neuberger Berman Group#7 · 31,886 sh | 31,886 | $33.5K | 0.00% | 0.0% |
| 8 | XTX Topco Ltd#8 · 29,342 sh | 29,342 | $30.8K | <0.01% | -18.6% |
| 9 | JANE STREET GROUP#9 · 25,761 sh | 25,761 | $27.0K | 0.00% | +102.7% |
| 10 | VANGUARD FIDUCIARY#10 · 24,016 sh | 24,016 | $25.2K | 0.00% | 0.0% |
| 11 | STATE STREET#11 · 20,543 sh | 20,543 | $21.6K | 0.00% | 0.0% |
| 12 | HRT FINANCIAL#12 · 20,336 sh | 20,336 | $21.0K | <0.01% | New |
| 13 | Parallel Advisors#13 · 12,569 sh | 12,569 | $13.2K | <0.01% | 0.0% |
| 14 | NORTHERN#14 · 11,921 sh | 11,921 | $12.5K | 0.00% | 0.0% |
| 15 | Ground Swell Capital#15 · 10,752 sh | 10,752 | $11.3K | 0.01% | New |
| 16 | WELLS FARGO & COMPANY#16 · 6,257 sh | 6,257 | $6.6K | 0.00% | -11.1% |
| 17 | UBS Group AG#17 · 4,133 sh | 4,133 | $4.3K | 0.00% | -11.0% |
| 18 | Tower Research Capital (TRC)#18 · 3,984 sh | 3,984 | $4.2K | <0.01% | -6.2% |
| 19 | MORGAN STANLEY#19 · 871 sh | 871 | $915.00 | 0.00% | -8.1% |
| 20 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT#20 · 817 sh | 817 | $858.00 | 0.00% | 0.0% |
| 21 | Clean Yield Group#21 · 418 sh | 418 | $439.00 | <0.01% | 0.0% |
| 22 | NVWM#22 · 84 sh | 84 | $88.00 | — | 0.0% |
| 23 | BARCLAYS PLC#23 · 42 sh | 42 | $44.00 | 0.00% | New |
| 24 | SBI Securities , Ltd.#24 · 33 sh | 33 | $35.00 | — | 0.0% |
| 25 | Allied Private Wealth#25 · 32 sh | 32 | $31.00 | 0.00% | — |
| 26 | VIMA#26 · 17 sh | 17 | $18.00 | — | — |
| 27 | ROYAL BANK OF CANADA#27 · 9 sh | 9 | $0.00 | 0.00% | -82.4% |
| 28 | FMR#28 · 0 sh | 0 | $0.00 | 0.00% | -100.0% |
Funds that sold out of COCP in Q2 2026 (6)
Held COCP at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| T3 Companies51,500 sh | 51,500 | $52.0K |
| TWO SIGMA SECURITIES15,255 sh | 15,255 | $15.4K |
| Virtu Financial13,080 sh | 13,080 | $13.0K |
| FMR334 sh | 334 | $337.00 |
| MAI Capital Management237 sh | 237 | $240.00 |
| CITIGROUP1 sh | 1 | $1.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.